Search

Search Constraints

You searched for: Author/Creator McLaughlin, Peter

Search Results

1. High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. (24th March 2017)

2. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma. (10th August 2015)

3. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma. (28th February 2019)

4. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high‐risk follicular lymphoma due to severe haematological and infectious toxicity. (18th December 2015)

7. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Issue 1 (2nd January 2021)

8. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Issue 1 (2nd January 2021)

9. Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center. (9th December 2015)

10. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model. (22nd July 2016)